Cutaneous melanoma
Drug research and approvals for cutaneous melanoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 478 studies of cutaneous melanoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 478
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 0
- A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of…NCT07940881 · Phase 1 · SystImmune Inc. · starts Aug 24, 2026
- A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal…NCT07934927 · Phase 2 · Sun Yat-sen University · starts Sep 29, 2026
- Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA MonitoringNCT07930182 · Phase 2 · H. Lee Moffitt Cancer Center and Research Institute · starts Oct 21, 2026
- High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal…NCT07913412 · Not reported · University Hospital, Essen · starts Sep 1, 2019
- Using an Artificial Intelligence (AI) Tool for Melanoma DiagnosisNCT07890415 · Phase 3 · Memorial Sloan Kettering Cancer Center · starts Oct 15, 2026
- Development and Multi-Centre Validation of a Novel Non-Invasive Melanoma Molecular Diagnostic TestNCT07883954 · Not reported · Mitra Bio · starts Jun 10, 2026
- Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a SystemNCT07870265 · Not applicable · Masaryk Memorial Cancer Institute · starts Oct 20, 2026
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug…NCT07863024 · Phase 1 / Phase 2 · Regeneron Pharmaceuticals · starts Oct 28, 2026
- SI-B036-ST-101 in Advanced/Metastatic Solid TumorsNCT07857616 · Phase 1 · SystImmune Inc. · starts Jul 30, 2026
How its trials ended
221 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 59 whose ending is known, 36% met their primary endpoint, 5% missed it and 59% stopped early.
- Ongoing9945%
- Completed, result not reported5625%
- Met its primary endpoint2110%
- Stopped: other or unclear188%
- Stopped: enrollment or feasibility105%
- Status unknown73%
- Missed its primary endpoint31%
- Stopped: sponsor or business decision31%
- Stopped: funding31%
- Stopped: lack of efficacy1<1%
| Nov 14, 2025 | Suprame - actengine IMA203 vs. investigator's choice of treatment in previously treated, unresectable or metastatic cutaneous melanomaIMA203 / Proleukin | Immatics US, Inc. | Ongoing |
| Jul 29, 2024 | A randomized, open-label phase 3 study in patients with previously treated unresectable or metastatic nras mutant cutaneous melanoma comparing the combination…Naporafenib (LXH254, ERAS-254)/ Trametinib (TMT212) | Erasca | Closed |
| Jul 5, 2023 | A phase 1 study of INCB099280 in combination with ipilimumab in participants with select solid tumorsINCB099280 / Ipilimumab | Incyte | Closed |
| May 20, 2020 | The response to intralesional IL-2 and/or bcg treatment for cutaneous metastatic melanomaProleukin (aldesleukin) / Oncotice (bacillus calmete guerin, strain tice) /… | Nova Scotia Health Authority | Pending |
| Jul 2, 2014 | Adjuvant pegylated-interferon-ALPHA2B (sylatrontm) for two years vs observation in patients with an ulcerated primary cutaneous melanoma t (2-4)BN0M0: a…Peginterferon ALFA-2B | Ncic Clinical Trials Group Queens University | Pending |
| Oct 28, 2015 | YervoyFor the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who… | Bristol-Myers Squibb Company | Approved |
| Feb 3, 2026 | An adoptive cellular therapy (ACT) based on the use of…Treatment of Stage II and higher cutaneous melanoma (CM), in human leukocyte antigen (HLA)-A*02:01-positive patients | Immatics US, Inc | Designated |
| Nov 12, 2008 | Melphalan hydrochlorideTreatment of patients with cutaneous melanoma. | Delcath Systems, Inc. | Designated |
| Sep 19, 1994 | Monoclonal Ab(murine) anti-idiotype melanoma-associated…Treatment of invasive cutaneous melanoma. | IDEC Pharmaceuticals Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA